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Megakaryocytes (MKs) are specialised cells which function to produce platelets and release 
them into the blood stream. MKs descend from hematopoietic stem cells (HSCs), via a 
stepwise differentiation model. A reduction in platelet number or function is described as 
thrombocytopenia and is typically accompanied by bleeding abnormalities. Surprisingly, a 
mutation in CYCS, the gene encoding cytochrome c, was identified in patients who had 
thrombocytopenia but no other deficiencies. This prompted the need for investigation into the 
energy demands of MKs as there is currently no understood role for cytochrome c in 
thrombopoiesis. To do so, a MK cell model was developed using K562 cells and phorbol 12-
myristate 13-acetate (PMA). To elucidate a megakaryocytic specific function for cytochrome 
c, the mitochondrial respiratory capacity of the cell models was explored. Cytochrome c 
shuttles electrons via redox reactions in the electron transport chain (ETC); therefore, it was 
hypothesised that MKs may have specific energy demands that lead to thrombocytopenia in 
patients with CYCS mutations. Furthermore, this study aimed to test whether inhibition of 
mitochondrial ROS impacted on the megakaryocytic differentiation capability of K562 cells.  
 
It was determined that treatment with 0.5 nM PMA for three and six days represented a 
partially and fully differentiated megakaryocyte respectively. This cell model was used in 
further experiments looking at the energy demands of megakaryocytes. Using the Seahorse 
Cell Mito Stress test, the mitochondrial respiratory capacity was compared between wild type 
(WT) K562 cells and the differentiating MK cell models. Although no significant differences 
in the energy demands of MKs throughout differentiation were noted, this study suggests that 
partially differentiated MKs had increased maximal and spare respiratory capacity. K562 
cells treated with mitochondrial inhibitors and PMA did not show any significant results 
when comparing their differentiation capability to cells with PMA alone. There did appear to 
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be a positive correlation between CD61 mean fluorescent intensity (MFI) and oxygen 
consumption rate (OCR). 
 
These results suggest that there is variation in the energy demands of MKs as they 
differentiate, however the findings are inconclusive. Further study should be done to confirm 
the observations made of the increased maximal and spare capacity of partially differentiated 
megakaryocytes. It would be beneficial to re-define a partially and fully differentiated MK 
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The bone marrow is a major hematopoietic organ in the central cavities of long and axial 
bones. It is responsible for producing erythrocytes, granulocytes, monocytes, lymphocytes, 
and platelets from hematopoietic stem cells (HSCs) during hematopoiesis. Hematopoiesis is 
compartmentalised to the hematopoietic tissue, and during maturation various hematopoietic 
cells migrate to the vascular niche at the centre of the bone marrow ready for distribution into 
the vascular sinus. The edge of the bone marrow has a higher oxygen concentration compared 
to the osteoblastic niche where HSCs reside; this oxygen gradient facilitates a variety of 
regulatory processes.  
 
Megakaryocytes (MKs) are a myeloid derived hematopoietic cell which are found in the bone 
marrow and are highly specialised to produce platelets. MKs make up less than 0.1% of total 
cells found within the bone marrow making them difficult to study, resulting in little 
knowledge around how these cells behave within the bone marrow environment. This project 
aims to investigate the metabolism of MKs to understand how a mutation in cytochrome c 
manifests thrombocytopenia. Thrombocytopenia is a disease characterized by a reduction in 
platelet number or function, often leading to bleeding abnormalities in patients. 
Thrombocytopenia can be inherited, manifesting from mutations that disrupt MK 
development, activity, or platelet function. Interestingly a mutation in CYCS, that encodes 
cytochrome c, was identified in a family with mild non-syndromic thrombocytopenia1. 
Currently there is little understanding of MK cellular bioenergetics and how individuals with 
a variant cytochrome c can present with thrombocytopenia but no other mitochondrial 
deficiencies.  
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1.1 Megakaryocyte development  
MKs mature in the bone marrow through a series of differentiation steps initiating from 
HSCs (figure 1.1). The classical model of hematopoietic hierarchy has been well accepted for 
several years since the classification and isolation of HSCs2. This model proposes a relatively 
simple, linear pattern of differentiation whereby one major bifurcation divides progenitor 
cells into lymphoid and myeloid lineages from a multipotent progenitor cell (figure 1.1). 
Common myeloid progenitor cells then differentiate into megakaryocyte-erythrocyte 
progenitors before maturing into MKs, in a model that suggests MKs mature through 
multiple intermediate states of differentiation3. MK lineage commitment is driven by multiple 
factors however, it is well established that thrombopoietin (TPO) is the key driver of this 
process. HSCs and MKs both possess the TPO receptor, c-mpl, outlining TPO is required 
throughout MK differentiation4. Multiple surface receptors are shared between cells with 
megakaryoblastic potential and MKs themselves, including a heterodimeric glycoprotein 
complex comprised of GpIIb and GpIIIa5. This glycoprotein receptor is known as the platelet 
fibrinogen receptor important for platelet aggregation and well established to mark MK 
maturation6. Due to the shared surface receptor protein expression, the mode of MK 
differentiation has recently been in question. MKs and HSCs share an assortment of receptors 
and cell surface markers, including c-mpl, leading to speculation that the two cell types are 
more closely related than originally thought. Some studies have suggested that MKs may not 
only develop through a stepwise differentiation model as outlined by the classical model, but 
furthermore may have the capacity to mature directly from HSCs and potentially even from 
lymphoid progenitors7, 8 (figure 1.1). 
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Figure 1.1 Megakaryocyte differentiation models. A. Classic model of HSC differentiation. HSC 
differentiate to CMP, then MEP, finally to MK. Mature MK undergo polyploidization and grow. 
Furthermore, cytoplasmic re-modelling occurs in mature MK to project proplatelets. Proplatelets extend 
into the vascular sinus where the flow of blood causes their tips to break off releasing platelets. HSC 
reside in the osteoblastic niche and as they differentiate, move to the centre of the bone marrow, the 
vascular niche. TPO is implicated in the process driving HSC commitment down MK cell lineage. B. 
Alternative models of HSC differentiation. New evidence supports presence of LMPP which may have 
the capacity to differentiate to MEP as well as down lymphoid lineage. New evidence furthermore 
supports HSC direct differentiation to MK, or differentiation through an unidentified intermediate cell. 
Abbreviations: Hematopoietic stem cell (HSC). Common myeloid progenitor (CMP). Megakaryocyte-
erythrocyte progenitor (MEP). Megakaryocyte (MK). Lymphoid-primed multipotent progenitor 
(LMPP). Granulocyte-macrophage progenitors (GMP).  
 
Studies supporting these alternative models have been completed in mice and therefore these 
ideas are currently restricted to murine hematopoiesis. However, the findings are important as 
it outlines that there is the possibility of multiple MK differentiation avenues in mammalian 
tissue. Alternative HSC MK differentiation models still largely describe multiple MK 
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progenitor cells, therefore it is possible to conclude that MKs exist in the bone marrow at 
varied stages of differentiation.  
 
Mature MKs function to produce platelets that travel in the blood stream and help maintain 
hemostasis by initiating tissue healing post vascular injury. During maturation MKs undergo 
endomitosis resulting in large polyploid cells. Reasons for MK polyploidisation are not 
currently understood, however speculation surrounds its importance in meeting potential 
increased energy demands of mature MKs. To release platelets into the blood stream, MKs 
undergo extensive morphological changes whereby the cytoskeleton is reorganized so that 
long, cytosolic branches are extended out from the MK cell body9. These branches are known 
as proplatelets and reach into the vascular sinus where the flow of blood causes their tips to 
break off releasing platelets. Formation of proplatelets proceeds the development of the 
invaginated membrane system (IMS)10. Throughout maturation as the MK undergoes 
morphological changes, the IMS forms continuous with the plasma membrane and permeates 
the cytoplasm. The morphological changes that mature MKs endure are thought to be energy 
expensive processes, although this remains untested. It has been known since early platelet 
and MK studies that the IMS forms the platelet membrane11, 12, and more recently has been 
implicated with proplatelet formation as the two both express PI-4,5-P2, a key phospholipid 
typically confined to internal membranes13. Deficiencies in proteins which regulate IMS and 
proplatelet formation, such as CIP4, lead to thrombocytopenia linking the IMS and 
proplatelet formation, again highlighting both their importance in platelet production14.  
 
Proplatelets extend from a single site in mature MKs and act as platelet production lines. The 
use of confocal imaging has allowed for proplatelet imaging revealing mechanisms by which 
the MK produces platelets15. Platelet sized swellings along the proplatelet shaft post 
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rearrangement of the cytoplasm in MKs were observed15. These platelet sized swellings 
translocate along the proplatelet branch, reaching the tip until they are sheathed off by the 
flow of blood in the vascular sinus. Proplatelets are dynamic, extending out from the 
cytoplasm of MKs until only the multi-lobed nucleus is left, resulting in thousands of 
platelets produced from a single MK15. In situations of acute platelet need, platelets lacking 
the marginal microtubule coil are released from thick protrusions of immature proplatelets16, 
or through MK rupture17. MKs rely on dynamic adaptive activities, therefore it is possible 
that they have high energy requirements to facilitate such needs, however, due to lack of a 
suitable protocol, MK metabolism is largely untested.  
 
1.2 Thrombocytopenia  
Thrombocytopenia is a disease characterized by reduced platelet number or function. 
Platelets are integral to the maintenance of vascular endothelium by initiating healing post 
injury. Activated platelets adhere to the exposed subendothelial extracellular matrix through 
interactions between platelet surface receptors such as GPIb, GPIb, and GPIX that bind 
Von-Willebrand factor18. This process facilitates platelet adhesion, and the injured site is 
barricaded to prevent blood loss. Activated platelets recruit circulating platelets for 
coagulation and initiate thrombus formation, allowing tissue healing to occur19. As the 
injured site is barricaded and bleeding resolved, a series of negative self-regulatory factors 
prevent the thrombus from growing too large. In cases of thrombocytopenia, there are either 
too few or ineffective platelets to control bleeding and promote tissue regeneration. 
Individuals typically present with bleeding abnormalities; in mild cases they are susceptible 
to bruising, however in some cases can manifest extreme bleeding conditions and blood loss.   
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Thrombocytopenia was first classed as an acquired disease with various causes such as 
adverse drug reactions stimulating an immune response, bacterial and viral infection, or 
arising secondary to major illnesses20. The first inherited thrombocytopenia was classified in 
1948 by Professor Jean Bernard and Jean-Pierre Soulier who described a congenital platelet 
defect with abnormally large platelets, known as Bernard-Soulier syndrome20. Mutations in 
platelet surface receptors GPIb, GPIb, and GPIX disrupted the binding of Von-Willebrand 
Factor ultimately leading to disordered platelet adhesion. Currently, over 40 genes have been 
classified as causative of inherited thrombocytopenia20. Many of these genes are implicated 
in platelet biogenesis or function, and therefore it is clear to see how they correlate with 
thrombocytopenia. For example, mutations in cytoskeletal genes such as TUBB1, disrupt 
microtubule assembly impacting on the ability of MKs to form proplatelets, therefore 
reducing overall platelet concentration21. The discovery of a mutation in CYCS in individuals 
with mild non-syndromic thrombocytopenia was surprising as there is currently no specific 
role for cytochrome c outlined in thrombopoiesis. How CYCS mutations are associated with 
thrombocytopenia, yet the patients exhibit no other mitochondrial deficiencies remains 
elusive. Four mutations in CYCS have been associated with thrombocytopenia, the first 
identified being G41S1 followed by the characterization of Y48H22, A51V23, and most 
recently K100del24.  
 
1.3 Cytochrome c  
CYCS encodes cytochrome c, a highly conserved small heme protein that has multiple 
functions dependent on its location within the cell. Typically, cytochrome c resides on the 
mitochondrial membrane where it acts as an electron shuttle between complex III and IV 
(figure 1.2A)25. Cellular stress leading to DNA damage permeabilises the outer mitochondrial 
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membrane and cytochrome c is released. In the cytosol, cytochrome c activates apoptosis 
activating factor 1 (Apaf-1) facilitating its’ binding to caspase enzymes, subsequently 
forming the apoptosome (figure 1.2B)26.  
 
 
Figure 1.2. Overview of cytochrome c functions in apoptosis and electron transfer. A. Schematic 
of the electron transport chain. NADH and FADH2 donate electrons to complex I and II respectively. 
The electrons are passed to ubiquinone (Q). Cytochrome c is found on the inner mitochondrial 
membrane where it acts as an electron carrier between complex III and IV. Complex III reduces 
cytochrome c, facilitating electron transfer to complex IV. Complex IV reduces oxygen to water, 
cytochrome c is oxidized and cycles back to complex III. Electron transfer is coupled with H+ movement 
at complexes I, III, and IV resulting in the formation of an electrochemical gradient. B. Cytochrome c 
(cyt c) is released from the mitochondria where it binds apoptosome activating factor 1 (Apaf-1). Active 
Apaf-1 and cyt c then bind caspase-9 to initiate formation of the apoptosome beginning the intrinsic 
apoptotic pathway, leading to eventual cell death.  
 
The impact that mutations in CYCS have on cytochrome functionality have been 
controversial. The study that first described G41S variant cytochrome c reported no change in 
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redox potential when compared to wild type cytochrome c by investigating purified MK stem 
cells from affected family members1. A subsequent study that identified cytochrome c variant 
Y48H, reported decreased oxygen consumption for both the Y48H and G41S variants using 
mice and yeast cells22. It is possible that these differences are due to variability between 
human, murine, and yeast cells. Structural analysis of cytochrome c variants G41S, Y48H, 
and A51V indicated that at steady state they favoured the ferric form, suggesting a reduction 
in its electron transfer activity27. Furthermore, this study indicated increased peroxidase 
activity for the three variants27, contradicting a later report that detailed no significant change 
in the redox potential or peroxidase activity for any cytochrome c variant28. Evidently, the 
discrepancies in the literature indicate that there is further work required to elucidate the 
impact CYCS mutations have on the function of cytochrome c in mitochondrial respiration.  
 
The impact that CYCS mutations have on cytochrome c’s role in apoptosis have also been 
controversial. Initially it was thought that increased apoptotic activity of variant cytochrome c 
could explain thrombocytopenia1. Using CD34+ blood cell derived MKs, platelets were 
produced after only six days in culture; typically, CD34+-derived MKs produce platelets after 
10-12 days1 leading to speculation that enhanced apoptosis was a feature of variant 
cytochrome c that may lead to thrombocytopenia. This idea was supported by De Rocco et al. 
(2014) who first described the Y48H variant alongside enhanced apoptotic activity for both 
Y48H and G41S variants22. Later studies have since raised questions around the role of 
apoptosis in thrombopoiesis and its implication in thrombocytopenia. Transmission 
microscopy using samples from affected individuals with cytochrome c associated 
thrombocytopenia showed a normal MK population with no apoptotic MK within the bone 
marrow itself29. Furthermore, using peripheral blood samples from patients, these cells 
responded in a normal manner to apoptotic stimuli29. These findings suggest that cytochrome 
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c variants do not impact on its apoptotic activity significantly in vivo, and therefore the 
enhanced apoptotic activity of variant cytochrome c is unlikely to be causative of 
thrombocytopenia. This has since led to increased speculation around cytochrome c and its 
role in MK mitochondrial respiration, whereby there may some feature unique to the bone 
marrow environment causing an alternate function of variant cytochrome c leading to 
thrombocytopenia. Furthermore, the role of apoptosis in thrombopoiesis in general has no 
clear definition. Initially it was thought that apoptosis was required for platelet production, 
leading to a large volume of reports using cell culture methods to support this idea. More 
recent evidence from mice studies suggests that apoptosis must be restrained for platelet 
production. The use of transgenic mice with enhanced apoptotic activity did not have a 
significant reduction in platelet production30, nor did the loss of pro-apoptotic factors in mice 
reduce platelet number31. The non agreeance of the function of variant cytochrome c in 
respiration indicates a need for further investigation, highlighted by the controversies 
surrounding apoptosis and thrombopoiesis.  
 
1.4 Mitochondria  
Mitochondria are present in every eukaryotic cell, aside from erythrocytes, and contribute to 
cell homeostasis through production of ATP via oxidative phosphorylation. The process 
involves the electron transport chain (ETC), where protein complexes convert chemical 
energy stored in nutrients to an electrochemical gradient (figure 1.2A) that is used to power 
complex V and produce ATP32. The ETC sits on the inner mitochondrial membrane, near the 
main source of energy for cells, the tricarboxylic acide (TCA) cycle. The TCA cycle feeds in 
substrates FADH2 and NADH via the oxidation of acetyl-CoA produced from the breakdown 
of carbohydrates, proteins, and fats33. FADH2 and NADH are reduced, and electrons are fed 
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to complex I and II respectively (figure 1.2A). Electrons are shuttled through the ETC via a 
series of redox reactions. Cytochrome c is reduced by complex III, facilitating electron 
transfer to complex IV (figure 2A)33. Oxygen acts as the terminal electron acceptor, forming 
H2O33. As electrons pass through the ETC, at complex I, III and IV, protons are moved from 
the mitochondrial matrix into the intermembrane space establishing the proton motive force 
(figure 1.2A). The proton motive force is a combination of the proton concentration (pH) and 
the electrochemical gradient across the mitochondrial membrane34. As protons re-enter the 
mitochondrial matrix, they move through complex V which in turn converts ADP to ATP, a 
process referred to as coupled respiration34. Uncoupled respiration occurs when the proton 
motive force is broken down, most commonly via uncoupling proteins, and occurs at the 
expense of ATP production. ATP produced via the mechanism described above is referred to 
as oxidative phosphorylation and accounts for the majority of ATP production in the body. 
ATP is also produced independently of the mitochondria via glycolysis which involves the 
breakdown of glucose to pyruvate35.  
 
Mitochondria are furthermore responsible for production of reactive oxygen species (ROS). 
Traditionally it was believed that mitochondrial ROS were harmful by-products of 
respiration, however in recent years a growing body of evidence supports their essential role 
in a variety of cellular processes. ROS are produced via electron leak from redox sites in the 
ETC36. In the mitochondrial matrix, oxygen resides as the terminal electron acceptor in the 
ETC and premature single electron release leads to the formation of superoxide from 
molecular oxygen, subsequently forming hydrogen peroxide36. Complex I and III are 
responsible for the majority of ROS production, however there are five other sites capable of 
producing ROS36. ROS may have an important role in the bone marrow influencing signaling 
events during hematopoiesis37. The source of ROS in bone marrow cells is currently 
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understood to arise from NADPH oxidase enzymes (NOX) on the plasma membrane, where 
production of superoxide can promote signaling events controlling cell differentiation. 
Increased ROS levels were reported when growth factors TPO, interleukin 3 (IL-3), and 
granulocyte-macrophage-colony-stimulating factor (GM-CSF) were added in vitro, 
suggesting that ROS are implicated in MK differentiation38. Currently it is unknown what 
contribution mitochondrial ROS make towards MK differentiation.  
 
A recent publication has suggested that oxidative phosphorylation plays an important role in 
the onset of thrombopoiesis in MKs, outlining that a switch in energy metabolism likely 
occurs as HSCs differentiate down MK lineage39. HSCs are well understood to utilize 
glycolysis as a method for coping with the hypoxic conditions in the bone marrow40. The 
antioxidant N-acetyl cysteine (NAC) reduced proplatelet forming MKs derived from CD34+ 
HSCs, while the pro-oxidant NAM increased proplatelet formation suggesting that ROS are 
important in the production of platelets39. Inhibition of NOX showed no change in the 
capability of MKs to produce proplatelets, however specific inhibition of mitochondrial 
superoxide anions significantly lowered the number of proplatelet forming MKs39. These 
results highlight that mitochondrial ROS may be important for thrombopoiesis, although it is 
not yet conclusive.  
 
1.5 Mitochondrial respiration in megakaryocytes 
Different cells are dependent on mitochondria in different ways; for example cardiomyocytes 
rely on mitochondria for over 95% of their energy production41, whereas endothelial cells 
rely on glycolysis for energy42.  It is therefore entirely possible that MKs have unique 
mitochondrial needs. It has been reported that oxazolidinones, a class of antibiotics, cause 
thrombocytopenia as a side effect by inhibiting the activity of cytochrome c oxidase43. When 
 12 
evaluating these side effects, it was observed that by rescuing complex IV, the 
thrombocytopenic phenotype reclined44. This suggests that oxidative phosphorylation is 
important in thrombopoiesis as by reducing its capacity a thrombocytopenic phenotype 
develops. These individuals do not show any other mitochondrial deficiencies43, again 
implying that the energy demands within MKs are unique, although this has not yet been 
explored. Mitochondrial metabolism in MKs remain elusive as studies have thus far focused 
on mitochondrial ROS production rather than specifically investigating MK mitochondrial 
function. It is possible that MKs at different stages of development have varied energy 
requirements due to their different sizes and activities. The vast morphological changes MKs 
undergo during development to produce platelets are potentially energy extensive processes, 
therefore MKs may rely on oxidative phosphorylation for energy as this produces a higher 
ATP yield than glycolysis. This idea remains untested, with no clear evidence on the energy 
demands of MKs.  
 
1.6 Research aims and hypotheses  
It is hypothesised that mitochondrial activity will alter between MKs at varied stages of 
differentiation. This is in part due to the increased size of mature MKs, and furthermore due 
to the varied bone marrow environmental conditions between the osteoblastic niche where 
immature MKs reside and the vascular niche where mature MKs are found. There is evidence 
that mitochondrial ROS are involved in thrombopoiesis, and it is possible that mature MKs 
rely differently on their mitochondria compared to immature MKs. To test this, a MK cell 
model will be established for partially differentiated, and fully differentiated MKs. The 
oxygen consumption rate (OCR) will then be compared between differentiating MKs. Further 
investigation of the energy demands of MKs will include the use of mitochondrial ROS 
inhibitors to assess the impact of mitochondrial ROS on MK differentiation.  
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It is possible that variant cytochrome c proteins will alter the mitochondrial function in MKs, 
which may lead to altered platelet production efficiency, in part elucidating the association 
between CYCS mutations and thrombocytopenia. To test this hypothesis, K562 cells 
expressing variant cytochrome c proteins via CRISPR-Cas gene editing will be constructed. 










2. Materials and methods 
This project involved comparing the cellular bioenergetics between MKs throughout 
differentiation. Furthermore, it aimed to look at the impact cytochrome c variants have on 
MK cellular bioenergetics. To do so, a cell model representative of MKs throughout 
differentiation was developed. A protocol for assessing the cellular bioenergetics of MKs 
using the Seahorse XF Cell Mito Stress test was optimised. Furthermore, K562 cells were 
transfected with variant cytochrome c plasmids in preparation for Seahorse XF Cell Mito 
Stress Test.  
 
2.1 General tissue cell culture  
Iscove’s Modified Dulbecco’s Medium (IMDM): One 500 mL packet of IMDM was mixed 
with one 20 mL aliquot of FBS and one aliquot of penicillin/streptomycin to give final 
composition of 10% FBS and 1% penicillin/streptomycin. Media was stored in 200 mL 
aliquots at 4C. IMDM purchased from Thermo Fisher (Cat. 12200028).  
 
Fetal bovine serum (FBS): Stored in 20 mL aliquots at -20C. FBS 500 mL purchased from 
Cytiva Global Life Sciences (Cat. SH3046.02).  
 
Penicillin/streptomycin: Penicillin purchased from Sigma (Cat. 69-57-8). Streptomycin 
purchased from Sigma (Cat. S9137).  
 
K562 cells were used for all experiments in this thesis, kindly donated by Dr. Maggie Kalev 
from the University of Auckland. STR analysis confirmed cell line was K562. Mycoplasma 
testing was clear. Cells were grown at 37C in an incubator supplemented with 5% CO2 in T-
25 or T-75 flasks. Media was changed every 2-3 days and new cultures were started at 1x105 
cells/mL. Cell counts were determined manually using a hemacytometer. Cells were 
harvested from the flask into a falcon tube and centrifuged at 165 g for 5 min before being 
resuspended in warmed IMDM for cell counting.  
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2.2 K562 cell differentiation 
Phosphate buffered saline (PBS): Purchased from Oxoid Ltd. (Cat. S9137).  
 
Phorbol 12-myristate 13-acetate (PMA): 1.25 L of 1 mg/mL PMA was diluted in 1998.75 
L DMSO, final stock concentration 0.5 nM. PMA purchased from Sigma NZ (Cat. P8139).  
 
Dimethyl sulfoxide (DMSO): Purchased from Thermo-Fisher (Cat. D 159-4).  
 
6 well plate (6 WP): Purchased from Cellstar via Grenier Bio-one (657160). 
 
 
2.2.1 Standard differentiation protocol  
PMA induces megakaryocyte-like K562 cell differentiation. Harvested K562 cells were 
resuspended in IMDM, and 2 mL of cell suspension was seeded at 0.5 x106 cells/well in 6 
WP. The plate was incubated for 15 min at 37C supplemented 5% CO2. After 15 min, 1.25 
L of PMA (0.5 nM) was added to each well. The plate was swirled gently to assure 
distribution of PMA throughout the cell solution. Cells were incubated for the desired time; 
three or five days. The assay was repeated as above for both six- and nine-day time courses to 
establish an intermediately differentiated and fully differentiated MK cell model.   
 
2.2.2 Differentiation optimisation protocol  
To try and prevent cell death, a differentiation optimisation assay was completed over six and 
nine days. Cells were treated as above (2.2.1). On day three, the media was changed for some 
wells and PMA was or was not added. On day six, media was changed again with or without 
the addition of PMA. The same assay was repeated for a six-day time course where the media 
was changed on day three with or without the addition of PMA.  
 
 16 
2.3 Poly-L-lysine adhesion test 
Poly-L-lysine: 0.01% Poly-L lysine solution purchased from Sigma-Alrich (Cat. P4707).  
 
24 well plate (24WP): Purchased from Cellstar via Grenier Bio-one (Cat. 662160).  
 
24 WP was coated with 150 L poly-L lysine and left to incubate at room temperature 
overnight on a shaker. After approximately 24 h excess poly-L-lysine was aspirated from the 
wells and the plate was left to air dry in the cell culture hood for 15 min. Wells were then 
washed twice with 500 L filter sterilised H2O. Post washing, 500 L of IMDM was added 
to each well and the plate was incubated at 37Co with 5% CO2 for at least two hours. K562 
cells were added to the wells in 500 L IMDM at concentrations ranging between 0.2x106 – 
0.6 x106/mL. The plate was incubated overnight at 37Co supplemented with 5% CO2. The 
following day photos were taken of each well before adhesion integrity was assessed by 
washing with PBS. Prior to wash steps, media was aspirated and transferred to Eppendorf 
tube to count cells and establish adherence success. Wells were then washed one or three 
times with 200 L PBS to ascertain adherence integrity. Photos were taken again post wash 
steps.  
 
2.4 Flow cytometry  
Flow cytometry staining (FACS) buffer: 0.01 g of 0.01% sodium azide, 0.1 g 0.1% BSA, 
100 mL PBS was added to beaker, filter sterilised, and stored at 4C.  
 
Sodium azide: Purchased from Sigma-Aldrich (Cat. S2002).  
 
Bovine serum albumin (BSA): Purchased from MP Biomedicals New Zealand Ltd. (Cat. 
219989880 – 100q).  
 
CD61 antibody: Purchased from BD Biosciences© (Cat. 555754). 
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Phycoerythrin (PE) antibody: Purchased from BD Biosciences© (Cat. 555749). 
 
After the differentiation protocol was completed, cells were harvested from 6 WP. Wells 
were washed once with 1 mL PBS and scraped to capture as many cells as possible, before 
being transferred to a 15 mL falcon tube. Cells were then centrifuged at 165 g for 5 min and 
then resuspended in 1 mL PBS. The cell suspension was split evenly (250 L per tube) 
between microcentrifuge tubes to obtain approximately 0.125 x106 cells (minimum number 
of cells required for guava flow cytometry analysis). Cells were then centrifuged at 1000 rpm 
for 5 min before excess PBS was removed. Cells were resuspended in 100 L PBS and 5 L 
of CD61 antibody, or 5 L of PE antibody was added to two separate samples. An unstained 
sample without the addition of antibodies was used as a negative control. Samples were 
incubated in the dark at room temperature for 30 min. After incubation, cells were 
centrifuged at 1000 rpm for 5 min and resuspended in 100 L PBS. Cells were centrifuged 
again at 1000 rpm for 5 min. Cells were resuspended in 600 L FACS buffer and 200 L of 
each sample was added to a 96 WP ready for analysis using the guava easycyte™ HT system. 
Analysis was completed using InCyte software. 
 
2.5 Cellular bioenergetics analysis 
To elucidate any potential variation in the mitochondrial respiratory demands of MKs during 
maturation, the Agilent Seahorse Cell Mito Stress Test was completed on wild type K562 
cells, and both partially and completely differentiated with PMA (as per materials and 
methods 2.2.2). All protocols were followed as per Agilent Seahorse user manuals.  
 
Seahorse XF kit: Purchased from Agilent via In Vitro Technologies (Cat. SEA 102416-100).  
 
 18 
2.5.1 Adhering suspension cells  
Cell-Tak: 61.7 L of 1.09 mg/mL Cell-Tak was diluted in 938.3 L filter sterilized MilliQ 
H2O to make 1 mL 22.4 g/mL working solution. Cell-Tak purchased from Abcam (Cat. 
Ab120081).  
 
Sodium bicarbonate (NaHCO3) solution: 50 mL 0.1 M working solution NaHCO3 was 
made with 0.42 g NaHCO3 and 40 mL MilliQ H2O. Sodium hydroxide (NaOH) was used to 
set pH to 8. 10 mL MilliQ H2O was then added to make 50 mL total. NaHCO3 purchased 
from Sigma-Aldrich (Cat. S-5761).  
 
K562 cells are suspension cells requiring immobilisation prior to the Seahorse Cell Mito 
Stress test. Seahorse XF 96 well plates were coated with Cell-Tak as per Agilent user guide 
‘Immobolisation of non-adherent cells with Cell-Tak for Assay’. Cell-Tak solution was 
prepared from stock to a concentration of 22.4 g/mL, and 10 L of working Cell-Tak 
solution was added to each well. NaHCO3 solution was then added to each well at a volume 
of 20 L, and the plate was left at room temperature for 20 min to ensure absorption to the 
wells. Wells were then washed twice with filter sterilized MilliQ H2O. Cell-Tak coated 
Seahorse XF 96 well plates were stored for up to one week at 4C.  
 
2.5.2 Seeding cells  
Seahorse XF RPMI media: Purchased from Agilent via In Vitro Technologies (Cat. SEA 
103576-100).   
Seahorse XF glutamine: Purchased from Agilent via In Vitro Technologies (Cat. SEA 
103579-100). 
Seahorse XF glucose: Purchased from Agilent via In Vitro Technologies (Cat. SEA 103577-
100). 
Seahorse XF sodium pyruvate: Purchased from Agilent via In Vitro Technologies (Cat. SEA 
103578-100). 
 
Media for Seahorse XF analysis was prepared with 0.5 mL glutamine (200 mM), 0.5 mL 
Seahorse XF glucose (1.0 M), 0.5 mL Seahorse XF sodium pyruvate (100 mM solution) and 
48.5 mL Seahorse XF RPMI medium. Harvested K562 cells were resuspended in 2 mL 
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Seahorse XF RPMI media to a concentration of 0.8x105 cells/50 L (or 1.6x106 cells/mL). 
To the corner wells, 50 L of Seahorse XF RPMI media was added. Cells were added to a 
sterile reservoir and 50 L cell suspension was gently pipetted down the side of each well 
using a multi-channel pipette. Each sample, wild type K562, K562 +PMA for three days, or 
K562 +PMA for six days, was added across four separate columns. The plate was centrifuged 
at 200 g with zero braking for 1 min. The plate was incubated at 37C without CO2 for 25-30 
min to ensure cell adherence. Seahorse XF media was added by gently pipetting 130 L 
down the side of each well, followed by a 30 min incubation at 37C without CO2. The plate 
was then put into the Seahorse XF analyser for OCR analysis.  
 
2.5.3 Cartridge hydration  
Seahorse XF calibrant solution: Purchased from Agilent via In Vitro Technologies (Cat. 
SEA 100840-000).  
20 mL Seahorse calibrant was aliquoted into a 50 mL falcon tube. The sensor cartridge was 
removed from the utility plate and placed upside down on the bench protecting the sensors. 
To hydrate the sensors, 200 L filter sterilized MilliQ H2O was added to each well of utility 
plate and the sensor cartridge was put back into the utility plate. The plate was incubated with 
the calibrant aliquot at 37C without CO2 overnight in a humidified container.  
 
2.5.4 Loading reagents 
Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP): FCCP was diluted to 10 
mM in DMSO and stored in 100 L aliquots at -20C. Purchased from Abcam (Cat. ab120081).  
Oligomycin: Diluted to 10 mM in DMSO and stored in 100 L aliquots at -20C. Purchased 
from Sigma-Aldrich (Cat. O4876).  
Rotenone: Diluted to 10 mM in DMSO and stored in 100 L aliquots at -20C. Purchased 
from Abcam (Cat. ab143145).  
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Antimycin A: Diluted to 10 mM in DMSO and stored in 100 L aliquots at -20C. Purchased 
from Sigma-Aldrich (Cat. A8674).  
Hoescht: 1 mg/mL aliquoted in MilliQ H2O and stored at -20C. 3 mL working solution diluted 
in Seahorse XF RPMI media to concentration 5 g/mL. Purchased from Invitrogen via Thermo 
Fisher© (Cat. H-1399).  
 
 
Table 2.5.1. FCCP and cell density optimisation experiments  













0.05 0.1 0.3 0.6 0.6 0.7 
0.15 0.2 0.4 0.7 0.7 0.8 
0.25 0.4 0.5 0.8 0.8 0.9 
0.35 0.8 0.6 0.9 0.9 1 
0.5  0.7  1  
0.75  0.8    
1  0.9    
1.1  1    
1.2  1.1    
2  1.2    
*Bold and italicised values refer to the optimised FCCP concentration and cell density. 
 
Reagent dilutions were carried out before Seahorse XF plate centrifugation to streamline the 
experimental timeline.  Reagent stocks (10 mM) were diluted in Seahorse XF RPMI media to 
a working concentration of 100 M for FCCP and oligomycin, and 50 M for both rotenone 
and antimycin A. Rotenone and antimycin A were prepared in one tube. FCCP was further 
diluted in Seahorse XF RPMI media to give a final well concentration of 0.8 M, and 
oligomycin and rotenone/antimycin A were diluted to give a final well concentration of 1.0 
M. Finally, 20 L oligomycin, 28 L FCCP, 25 L rotenone/antimycin A and 28 L 
Hoescht were loaded into ports. Various FCCP concentrations were tested as outlined in table 
2.5.1 prior to 0.8 M being chosen for future experiments.  
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2.5.5 Seahorse XF Mito Stress Test  
WAVE protocol: Three measurements over an 18min cycle for basal OCR. Three 
measurements in three 18min cycles post reagent injection. Custom cycle, 3min mix and 
30min paused post Hoescht injection to allow for cell staining.  
 
2.5.6 Normalisation method 
All Seahorse experiments were normalized to cell count using the Cytation automated cell 
counter. Cells were counted on both brightfield and DAPI settings. Brightfield was used 
majority of the time as the effectiveness of the Hoescht staining was variable. For 
experiments where the Hoescht staining was successful, brightfield counts were similar and 
therefore it was concluded that either cell counting setting was accurate.  
 
2.6 Mitochondrial ROS inhibitors  
S1QEL: Dissolved in 12.5 mL DMSO to make 4.58 mM stock and stored in 100 L aliquots 
at -20C. Purchased from Sigma (Cat. SML1948). 
S3QEL: Dissolved in 10 mL DMSO to make 15.488 mM and stored in 100 L aliquots at -
20C. Purchased from Sigma (Cat. SML1554). 
Harvested K562 cells were resuspended in IMDM, and 2 mL cell suspension was seeded at 
0.5 x106 cells/well in 6WP. Cells were treated with PMA as per above differentiation 
protocol (materials and methods 2.2). Next, 4.36 L S1QEL (10 M) or 1.3 L S3QEL (10 
M) was added to two wells treated with PMA, and to two wells without PMA. 3.0 L 
DMSO negative control was included. Plate was incubated at 37C with 5% CO2 for three 
days before analysis by flow cytometry (materials and methods 2.4).  
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2.7 Growing up transformed cells for K562 transfection 
Previously curated glycerol stocks of plasmids were used from Ledgerwood Lab stocks.  
2.7.1 Luria-Bertani (LB) broth preparation  
Yeast extract: 5 g.L-1. Purchased from Merk (Cat. MER103730500). 
Tryptone: 10 g.L-1. Purchased from Merk (Cat. MER107213). 
Sodium Chloride (NaCl): 10 g.L-1. Purchased from Stores (Cat. 7647-14-5). 
 
Yeast extract, tryptone, and NaCl were added to a 2 L cylinder which was then filled with 1 L 
distilled H2O. Using a magnet stirrer, the mixture was stirred for 20min. The pH was 
adjusted, if needed, with sodium hydroxide (NaOH) or hydrochloric acid (HCl) to 7.2. Once 
autoclaved, the mixture was split between sterile bottles and stored on the work bench at 
room temperature.  
 
2.7.2 LB Agar plates  
Agar: 15 g.L-1. Purchased from Applichem. (Cat. A0949). 
Ampicillin: 100 g/mL-1. Purchased from Roche Distributors. (Cat. 10 835 269 001).  
 
1.5 g yeast extract, 3 g tryptone, and 3 g NaCl were added to a 1 L cylinder. 300 mL distilled 
H2O was added and stirred using a magnet stirrer. pH should be 7.2 and was adjusted with 
sodium hydroxide (NaOH) or hydrochloric acid (HCl) accordingly. 4.5 g agar was added. 
Once autoclaved, 300 L ampicillin was added. Agar plates were poured following flaming 
the top of the cylinder. Plates were left to set on the work bench at room temperature.  
 
2.7.3 Growing up bacteria for plasmid DNA extraction  
MLM3636 sv neoR CYCS A51V gRNA plasmid: from Ledgerwood Lab stocks and stored 
at -80C 
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pcMV_AncBE4max_P2A_GFP plasmid: from Ledgerwood Lab stocks and stored at -80C 
Table 2.7.3. Plasmids used from Ledgerwood Lab stocks.  
Plasmid  DNA yield 








pCMV_ABEmax_P2A_GFP Base editing 
enzyme 
2570 ng/L 




A 2 L conical flask was cleaned with 70% ethanol before adding 500 mL of LB broth and 
500 L ampicillin (final solution 10% antibiotic). With a pipette tip, 4-5 bacteria colonies 
were gently removed from the agar plate and the whole tip was dropped into the flask. 
Careful consideration was taken to select single colonies where possible. The top of the flask 
was covered in tin foil and placed in a shaker set to 37C 200 rpm for at least 16 h. This 
protocol was carried out using aseptic technique by flaming pipette tips and the tops of flasks 
and tubes before adding any reagents.   
 
2.7.4 Plasmid DNA extraction  
ZymoPURE II midiprep kit: Purchased from Zymo via Ngaio Diagnostics (Cat. D4201).  
 
Cloudiness in the flask was indicative of bacterial growth. LB broth with signs of bacterial 
growth was split between 500 mL centrifuge tubes (125 mL per tube). Tubes were spun at 
1425 g for 20 min at 4C. DNA extraction was subsequently completed following 
ZymoPURE II midiprep protocol. The centrifugation protocol was followed and the 
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EndoZero II spin column was used to reduce the endotoxin concentration in the final DNA 
plasmid. DNA yield was quantified using the NanoDrop (absorption wavelength 260 nm) and 
plasmids were stored at -20C.  
2.7.5 NEON transfection 
The protocol in the NEON transfection system user guide was followed. Instead of R buffer, 
SBS buffer was used. To prepare cells, the suspension cell protocol was followed.  
SBS buffer: 250 mM sucrose was added to 100 mL PBS with 1 mM magnesium chloride 
(MgCl2). 
 
 Harvested cells were resuspended in complete IMDM and 500 L cell suspension was 
seeded in a 24 WP at a concentration of 0.2x106 cells/well and incubated overnight at 37C 
with 5% CO2. The following day, 500 L of warmed antibiotic free IMDM was added to 
each well of a 24 WP and incubated for approximately 30 min. K562 cells were harvested 
from 24 WP and resuspended in 2 mL warmed PBS. Cells were centrifuged at 1000 rpm for 
5min and resuspended in SBS buffer at volume of 12 L/well. Thawed plasmids were 
prepared in a 1.7 mL microcentrifuge tube: 1 L of MLM3636 sv neoR CYCS A51V gRNA 
plasmid and 2 L pcMV_AncBE4max_P2A_GFP plasmid were mixed in SBS buffer (10 
L/well). The volume of both plasmids was kept to less than 10% of NEON tip.  
 
K562 cells were electroporated using the 10 L NEON tip as per protocol in the NEON 









 Table 2.7.5 NEON transfection conditions.  
 
 
2.8 Statistical analyses 
Results from these experiments were analysed using a one-way ANOVA analysis on 
GraphPad. Corrections for multiple comparisons were completed using Dunnett post-hoc to 
determine whether results were statistically significant. Statistical significance was 








1 2 3 4 5 6 7 8 9 10 
Pulse 
voltage 
1400V 1400V 1450V 1450V 1450V 1500V 1500V 1550V 1550V 1400V 
Pulse 
width 
10 10 10 10 20 20 10 10 20 30 
Pulse 
number 
1 3 1 1 3 1 1 1 2 2 
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3 Results 
3.1 PMA-induced megakaryocytic differentiation   
To investigate mitochondrial activity in differentiating MKs, a suitable cell model needed to 
be established. K562 cells have been previously documented to differentiate into 
megakaryocyte-like cells with PMA45. K562 WT cells were initially treated with 0.5 nM 
PMA for three or five days. Flow cytometry detected levels of CD61 via 
immunofluorescence. CD61 is a MK differentiation marker, part of a glycoprotein complex 
expressed exclusively on the surface of MKs and platelets and is often used to classify MK 
differentiation5. K562 WT cells were used as a control for all experiments. A phycoerythrin 
(PE) isotype control sample was used across all differentiation experiments to account for 
potential background CD61 staining. No assays showed any indication of background CD61 
staining due to low levels of CD61 MFI in the PE isotype control sample (appendix A). The 
MFI was measured for all samples across all experiments using the Yellow-H-Log geometric 
mean to account for the logarithmic increase in fluorescence intensity. Fold change was 
calculated based on geometric mean from the unstained control for each sample. CD61 MFI 
increased as the time K562 cells were treated with PMA increased (figure 3.1.1). To establish 
an effective model for metabolism experiments, a partially differentiated, and fully 
differentiated cell model was required. It was unclear whether K562 cells treated with PMA 
for five days represented a fully differentiated or partially differentiated MK cell model from 
the data in figure 3.1.1. To confirm the most fully differentiated model, a longer time course 
was carried out.  
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Figure 3.1.1. PMA induces megakaryocytic differentiation of K562 cells. CD61 MFI of K562 cells 
incubated with PMA for either three or five days. Cells were then stained with CD61 antibody, a MK 
marker to establish amount of differentiation. Mean is geometric mean. Data is shown as a fold change 
in CD61 MFI from unstained undifferentiated sample for each population. n=3 for -PMA and +PMA 
3-day samples, n=1 for +PMA 5-day sample.  
 
K562 cells were treated with PMA for either three, six, or nine days (figure 3.1.2). 
Surprisingly, cells treated for nine days had reduced CD61 MFI compared to the three- and 
six-day samples (figure 3.1.2A). It would be expected that the nine-day sample would 
differentiate and express at least as much CD61 as the six-day sample, therefore it was 
postulated that by nine days the cell population wasn’t viable. An optimisation assay was 
then done where cells had their media changed at different time points to try and reduce cell 
death. PMA was added after some media changes. For all nine-day treatments with PMA, 
regardless of if the media was changed or if PMA was added, the fold change in CD61 MFI 































Figure 3.1.2. Long term PMA induced megakaryocytic differentiation of K562 cells. A. K562 cells 
were incubated with PMA for three, six, or nine days. CD61 MFI shown as fold change from unstained 
sample for each condition. Mean is CD61 geometric mean, n=1. B. Optimisation of long term K562 
PMA incubation. Cells were seeded at day zero and had their media changed either at day 3 three, six, 
or both, with or without the addition of PMA post media change for the nine-day protocol. Six-day 
differentiation samples were subjected to media change on day three with or without the addition of 
PMA. Control samples without media change or PMA added were included. Data is shown as a fold 
change in CD61 MFI from unstained sample for each condition. Mean is the geometric mean, n=1. 
 
In conclusion, K562 cells treated with PMA for nine days were likely not viable and 
therefore it was established that a six-day treatment with PMA was sufficient as a fully 




differentiated model. Changing the media did not appear to drastically alter the differentiation 
status of K562 cells compared to samples without any media change, hence it was not done 
for future experiments (figure 3.1.2B).  
 
 
3.2 Cellular bioenergetics of differentiating MKs 
To investigate the mitochondrial respiratory capacity of MKs throughout differentiation, 
K562 cells were treated with PMA to induce megakaryocytic differentiation. Cells were 
treated for three or six days, as described previously, to represent a partially and fully 
differentiated MK cell. Analysis of the oxygen consumption rate (OCR) in a partially, and 
fully differentiated MK like cell model was completed and compared to WT K562 cells using 
the Seahorse Cell Mito Stress test outlined in figure 3.2. All results were normalised to cell 
count as per materials and methods 2.5.6.  
 
The Seahorse Cell Mito Stress test measures the mitochondrial respiratory activities during 
both oxidative phosphorylation and glycolysis. Cellular metabolic fluxes during oxidative 
phosphorylation events are reflected by changes in the OCR in response to various reagents 
(figure 3.2), and the extracellular acidification rate (ECAR) reflects the glycolytic activity of 
live cells. ECAR predominantly correlates to the conversion of lactate to pyruvate which 
releases protons into the extracellular medium. After initial basal OCR measurements, 
oligomycin is injected which inhibits ATP synthase lowering the OCR allowing for analysis 
of mitochondrial respiration linked to ATP production (figure 3.2). A protonophore 
uncoupler, FCCP, is injected breaking down the proton gradient facilitating measurement of 
the maximal respiratory capacity. The combination of rotenone and antimycin A, which 
inhibit complex I and II respectively, break down the ETC and indicate non-mitochondrial 
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respiration. Prior to running the assay using the established MK cell model, it was important 
to optimise the cell seeding density and reagent concentrations.   
 
Figure 3.2. Agilent Seahorse XF Cell Mito Stress Test profile indicating the key parameters of 
mitochondrial respiration tested in the assay. Taken from the Agilent Cell Mito Stress Test Kit user 
guide.  
 
3.2.1 Seahorse XF flux experimental protocol optimisation 
K562 cell adhesion  
In order to carry out the Seahorse XF Cell Mito Stress test, suspension cells, such as K562, 
need to be adhered to the Seahorse XF plates. Two options were considered: poly-L-lysine 
and Cell-Tak. Poly-L-lysine is a poly amino acid that facilitates adherence of cells to solid 
surfaces. Poly-L-lysine enhances the electrostatic interactions between the cell culture surface 
and the cell membrane, creating several positively charged sites for interaction between cells 
and surfaces. For this reason, poly-L-lysine was chosen as a possible substrate to adhere 
K562 cells to Seahorse XF plates and a protocol was designed to obtain cell adherence. Three 
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wash steps were included in the optimisation protocol to account for the three reagents 
injected during Seahorse XF Cell Mito Stress test. Initial experiments confirmed that poly-L-
lysine was effective at adhering both WT K562 cells and K562 cells treated with PMA for 
three days in a 24 WP (appendix B). Experiments were then completed using a 96 WP to 
reflect the conditions of the Seahorse XF 96 WP. The Seahorse XF 96 WP has a smaller 
surface area than a standard 96 WP, and the cell concentrations seeded are representative of 
what would be seeded in the Seahorse XF 96 WP. Cells were adhered to the 96 WP as per 
materials and methods 2.3, and media was removed and kept for cell counting to establish the 
percentage of the seeded population that adhered. Table 3.2.1 outlines the percentage of the 
original cells seeded that remained post wash (x1 or x3). Percentages were calculated based 
on the assumption that the original cell population doubled after 24 h.   
 
Table 3.2.1. Percent of original cell population remaining post wash steps during poly-L 
lysine adhesion test 
Cell type Cell conc. x106/ml Post 1 wash (%) Post 3 washes (%) 
WT K562 0.6 95 81 
WT K562 0.2 100 75 
WT K562 0.05 93 42 
K562+PMA 
(3days) 
0.125 86 92 
K562+PMA 
(3days) 
0.25 92.4 80 
K562+PMA 
(5days) 
0.125 92 90 
K562+PMA 
(5days) 
0.25 92 98 
 
Corning Cell-Tak is a commercially available cell and tissue adhesive and is recommended 
by Agilent to immobilise suspension cells. Following the suspension cell immobilisation 
protocol from Agilent, WT K562 cells were seeded in Cell-Tak coated Seahorse XF 96 WP. 
Adherence was inspected via microscopy, and the cells were visually judged to have adhered 
(data not shown). The plate was then used in a preliminary Seahorse XF flux experiment that 
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tested if K562 cells responded to the reagents used and if Cell-Tak was a viable option for 
cell adherence. Images of some wells post Seahorse XF flux analyses shown in appendix C.  
The K562 cells showed a change in OCR post FCCP injection, and the trace was similar to 
the model Seahorse Cell Mito Stress test trace from the Agilent user manual (appendix F).  
 
In conclusion it was determined that Cell-Tak was the most suitable option for cell 
adherence. The adherence protocol was straight forward compared to the poly-L-lysine 
protocol as Cell-Tak coated plates could be prepared in advance and stored for up to a week. 
Furthermore, cells were seeded in Cell-Tak coated plates the day of the Seahorse XF flux 
analysis, unlike in poly-L-lysine coated plates which required an overnight incubation, 
potentially compromising cell health.  
 
Cell seeding density optimisation  
The basal OCR was used as a measure to determine the optimal seeding density for K562 
cells. An even cell monolayer was required for optimal assay conditions and adherence to 
Seahorse XF 96 WP. The literature reports a range of cell seeding densities for K562 cells in 
the Seahorse XF 96 WP, therefore, to determine the optimal cell seeding concentration, 
various cell densities were analysed as in figure 3.2.1. The optimal cell density was 
determined to be 0.8 x105 cells/per well based on figure 3.2.1B, whereby the mean basal 
OCR was 112 pmol/min/cell number and was the least variable between wells. This was 
similar to a previous study whereby 0.75 x105 cells/well were plated and basal OCR was 
approximately 180 pmol/min46. Some literature reported the concentration of K562 cells 
seeded in a Seahorse XF 96WP. Although the concentrations varied greatly, 0.8 x105 
cells/well frequented reports, and for this reason, alongside the justification outlined above, 
future Seahorse XF flux analyses were completed using 0.8x105 cells/well.  
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Figure 3.2.1. Seeding density optimisation experiments for K562 cells. A. Initial cell seeding density 
optimisation experiment. WT K562 cells were seeded at 0.1 x105, 0.2 x105, 0.4 x105, and 0.8 x105 
cells/well in Seahorse XF 96WP. Using the Seahorse XF flux analyser, basal OCR was measured from 
live cells. Data shown is the basal OCR for each well with mean ±SD, n=1. B. Experiment two 
comparing basal OCR of live WT K562 cells seeded at 0.7 x105, 0.8 x105, 0.9 x105, and 1.0 x105 
cells/well in Seahorse 96 WP. Data shown is the basal OCR for each well with mean ±SD, n=1.  
 
FCCP concentration optimisation  
To determine the optimal FCCP concentration, an assay was designed and run alongside the 
cell density optimisation. FCCP concentrations ranging from 0.05 M to 2.0 M were tested 






















































across multiple experiments. To determine the optimal FCCP concentration, the log2 fold 
change of OCR from basal to maximal respiration was calculated as shown in figure 3.2.2. 
As shown in Figure 3.2.2A, FCCP concentrations below 0.25 M elicited a weak increase in 
OCR as shown by log2 fold change less than 1 for all cell densities seeded. At concentrations 
above 1.0 M, FCCP appeared to have a negative effect on the increase in OCR from basal 
compared with lower concentrations (figure 3.2.2A) and therefore the optimisation assay was 
repeated using a narrower range (figure 3.3.2B). Similar increases in OCR were seen for all 
FCCP concentrations in figure 3.2.2B, besides wells seeded with 0.7 x105 cells. Ultimately, 
0.8 M was chosen as the optimal concentration as this concentration exhibited the most 
consistent increase in OCR from basal across wells at 0.8 x105cells/well (optimal cell 
density).  All optimisation experiments were completed using WT K562 cells. The results in 
figures 3.2.1 and 3.2.2 were assumed to also reflect that of K562 cells treated with PMA, 
therefore these cell densities and drug concentrations were used across all future Seahorse XF 
flux analyses. In the final optimisation experiment, 1.0 M oligomycin and 1.0 M 
rotenone/antimycin A were injected as recommended by Agilent. These drug concentrations 
produced a change in OCR within expected ranges and no further optimisation was deemed 




Figure 3.2.2. FCCP reagent concentration optimisation experiments. A. Experiment one trialling 
various FCCP concentrations to determine the optimal amount to illicit maximal change respiratory 
capacity. WT K562 cells were seeded at multiple cell densities (0.1 x105, 0.2 x105, 0.4 x105 and 0.8 
x105 cells/well). Each cell concentration was subjected to a range of FCCP concentrations. Data shown 
is the log2 fold change from basal OCR to maximal OCR recorded post FCCP injection. Data is from 
one experiment with 12 technical replicates. B. Experiment two investigating a narrower range of FCCP 
concentrations on multiple cell densities. WT K562 cells were seeded at varying cell densities (0.7 x105, 
0.8 x105, 0.9 x105 and 1.0 x105 cells/well). Data shown is the log2 fold change from basal OCR to 
maximal OCR recorded post FCCP injection. Data is from one experiment with 12 technical replicates. 
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3.2.2 Changes in mitochondrial respiration in response to stimuli 
in differentiating megakaryocytes  
Using the injection strategies outlined in figure 3.2, the mitochondrial respiratory capacity of 
K562 cells treated with PMA for three or six days (representative of partially and fully 
differentiated MKs) were compared to WT K562 cells. Figure 3.2.2.1A shows the mean 
changes in OCR in response to oligomycin, FCCP and rotenone/antimycin of WT K562 cells, 
and K562 treated with PMA for either three or six days. The trace suggests that K562 +PMA 
three days has the greatest OCR, potentially related to higher energy demands of 
differentiating MKs. Figure 3.2.2.1B quantifies the changes in OCR and relates these values 
to different parameters of mitochondrial respiration. As shown in figure 3.2.2.1B, the basal 
OCR was consistent across all cell populations. The mean basal OCR for undifferentiated and 
fully differentiated cells were identical (227 pmol/min/cell number), and the partially 
differentiated cell model was slightly increased at 277 pmol/min/cell number. Furthermore, 
ATP-linked OCR did not vary greatly between populations; the partially and fully 
differentiated populations were almost identical, and slightly less than the undifferentiated 
populations. Figure 3.2.3B suggests the partially differentiated cells had the greatest maximal 
respiratory capacity, and spare capacity (indicative of non-mitochondrial respiration). The 
variation in OCR between repeated experiments within each treatment group is greater for 
maximal respiratory and non-mitochondrial respiratory capacity (figure 3.2.2.1B). This 
makes it harder to draw conclusions about the energy requirements in differentiating MKs. 
An ANOVA one-way statistical analysis was completed between all samples and found no 
significant differences for any parameters tested, P > 0.05 (figure 3.2.2.1B). The results 
highlighted in figure 3.2.2.1B suggest that the cellular bioenergetics of MKs do not differ as 




























































Figure 3.2.2.1. Cellular metabolism of K562 cells treated with PMA. A. Changes in the oxygen 
consumption rate of K562 cells treated with or without (blue) PMA for three (red) or six (green) days. 
First three points indicate basal oxygen consumption rate. The following three points indicate changes 
in OCR measured post oligomycin (oligo) injection. The next three indicate the maximal respiration 
capacity measured post carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) injection. The 
final three points show a decrease in OCR post rotenone and antimycin A (R+A) injection, allowing for 
non-mitochondrial respiration to be determined. Data shown is mean  SD, n=3 for -PMA, n=5 +PMA 
3days, n=4 +PMA 6days, normalised to cell count. B. Comparison of OCR between partially 
differentiated (+PMA 3days) and fully differentiated (+PMA 6days) K562 cells. Data shown is mean  
SD, normalised to cell count. -PMA n=3, +PMA 3days n=5, +PMA 6days n=4, P  > 0.05.  
 
CD61 MFI of cell populations used in Seahorse Cell Mito Stress tests 
To determine levels of megakaryocytic differentiation, CD61 expression was calculated via 
flow cytometry on a sample of the cell populations used in the Seahorse Cell Mito Stress 
tests. Cells were treated as per the flow cytometry protocol in materials and methods 2.4. 
Flow cytometry analysis was completed on the same day as the Mito Stress tests to prevent 
cell death and most accurately reflect the differentiation status of the cells used in the assay. 
An unstained sample was a negative control for all experiments, and phycoerythrin (PE) 
antibody was used to control for non-specific CD61 staining, none of which was detected 
(appendix D). MFI was the geometric mean measured using Yellow-B-Hlog as per 
differentiation assays. For experiments three four and five, K562 cells treated with PMA for 
six days, representative of fully differentiated MKs, had lower CD61 MFI than those treated 
with PMA for three days (figure 3.2.2.2). Surprisingly, these samples did not reach the level 
of CD61 MFI seen in cells treated with PMA for three days. The first experiment (figure 
3.2.2.2) produced results consistent with earlier differentiation assay data whereby K562 cells 
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treated with PMA for six days had greater CD61 MFI than those treated for three days. CD61 
flow cytometry data was not collected for experiment two. The variability in the levels of 
differentiation observed raised questions to the validity of the MK cell models. 
 
 
Figure 3.2.2.2. CD61 MFI of cells used in Seahorse XF flux analysis is inconsistent with earlier 
differentiation data. The fold change of CD61 MFI of K562 cells +PMA for three or six days. Cells 
are from the same population used in the above Seahorse Mito Stress tests. Data shown is CD61 MFI 
fold change compared to unstained sample (UN) for each population. Mean is geometric mean, n=1. 
 
As shown in figure 3.2.2.2, the previously determined MK differentiation cell model was not 
replicated when completing Seahorse Cell Mito Stress tests. It was therefore concluded that 
cells treated with PMA for three days did not necessarily represent partially differentiated 
MKs, and cells treated for six days did not represent fully differentiated MKs.  
 
Correlation between CD61 mean fluorescent intensity and oxygen consumption rate    
As it is well understood that CD61 expression is a suitable MK maturation marker, the flow 
cytometry data was combined and analysed as one sample regardless of time treated with 
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PMA. This facilitated exploration of the possible correlation between OCR and CD61 MFI to 
determine whether there were any changes to the OCR of MKs as they differentiate. The 
mean OCR data from samples treated with PMA for three and six days was analysed as one 
sample population (figure 3.2.2.3). Analysis of the correlation between the two parameters 
was analysed on Graph Pad prism. The r values were greater than 1 for all parameters 
indicating a positive corelation between CD61 MFI and OCR (table 3.2.2). The r squared 
values indicate the level of shared variance between OCR and CD61 MFI. Nearly one third 
of the variance in maximal respiratory capacity is due to the level of CD61 MFI, suggesting 
that the maximum respiratory capacity is most dependent on differentiation status. The ATP-
linked respiratory capacity appears to be the least dependent on differentiation status (table 
3.2.2). However, the P values are all greater than 0.05, therefore the fact these correlations 
are due to chance cannot be excluded. The Pearson correlation does not report on non-linear 
relationships, therefore it is possible this was true for the populations, however was not 
reported on in this study.  
 
 41 
Figure 3.2.2.3. Correlation between OCR and CD61 in sample populations from Seahorse Cell 
Mito Stress tests. The correlation between OCR and CD61 MFI is shown using the mean OCR for 
each population from the different mitochondrial respiratory parameters tested. K562 cells were treated 
for three or six days with PMA to induce megakaryocytic differentiation. CD61 antibodies were used 
to indicate level of differentiation. OCR was measured using Seahorse Cell Mito Stress test. Table 3.3.2 





Table 3.2.2. Analysis of the correlation between OCR and CD61 MFI  









r 0.43 0.27 0.56 0.53 
P 0.29 0.52 0.15 0.18 
r squared 0.18 0.07 0.32 0.28 
Pearson correlation r and P values for correlation data between average OCR and CD61 MFI for 
K562 cells treated with PMA for either three or six days.  
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Energy phenotype of K562 cells treated with PMA 
The extracellular acidification rate (ECAR) measured in the Seahorse Cell Mito Stress test 
helps to determine the energy phenotype of cells. The glycolytic capacity of cells is reflected 
by the ECAR, which is a measure of the protons released into the extracellular medium from 
the conversion of glucose to lactate. As cells utilise glycolysis to produce energy, pyruvate is 
produced and is subsequently broken down into lactate47. The baseline ECAR was measured 
alongside OCR during the Seahorse Cell Mito Stress tests. The ECAR value for cells 
differentiated with PMA for three days was significantly higher compared to cells treated 
with PMA for six days. Initially it was thought that this showed MKs in an intermediate state 
of differentiation were more dependent on glycolysis at rest.  
Figure 3.2.2.4. Baseline ECAR for K562 cells. K562 cells were treated with or without PMA for three 
or six days. ECAR measured prior to oligomycin injection indicates the level of glycolytic activity 
within live cells. ECAR is measured concurrently with OCR during the Seahorse Cell Mito Stress test. 




Considering that there was no observed difference in OCR for K562 cells treated with PMA 
for three or six days, this result was unexpected and it is unlikely that it truly reflects the rate 
of glycolysis. It is more likely that PMA is having an effect on ECAR independent of 
differentiation. Based on the variability in the differentiation data for cells used in the 
Seahorse Cell Mito Stress test (figure 3.2.2.2), it is hard to draw conclusions on the energy 
use of differentiating MKs.  
 
3.3 Introducing CYCS mutations to K562 cells  
To elucidate a role for variant cytochrome c in the onset of thrombocytopenia, K562 cells 
expressing variant cytochrome c protein needed to be established. This would allow for the 
mitochondrial respiratory capacity of mutant K562 cells to be compared with WT K562 cells. 
Furthermore, the previously determined Seahorse Cell Mito Stress protocol could be applied 
to mutant cells allowing for analysis of their cellular bioenergetics. As part of a larger project 
looking at the impact of cytochrome c variants on cellular bioenergetics, the project focused 
specifically on the A51V variant and other lab members focussed on the Y48H and G41S 
variants. To create a K562 cell line expressing CYCS mutations, a modified CRISPR-Cas 
base editing system was used. This involves transfecting a base editing enzyme and variant 
specific guide RNAs into WT K562 cells. Adenine base editors are catalytically inactive and 
involve the deamination of adenosine to inosine. The inosine base is read by DNA 
polymerases as a guanine base, exchanging the A-T base pair to G-C in subsequent rounds of 
DNA replication48.  
 
The plasmids used are outlined in materials and methods 2.6, table 2.7.3; 
MLM3636_sv_neoR_CYCS_A51V_gRNA and pCMV_AncBE4max_P2A_GFP. DNA 
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extraction using the ZymoPURE produced yields of 1325 ng/L and 535 ng/L for the 
MLM3636_sv_neoR_CYCS_A51V_gRNA and pCMV_AncBE4max_P2A_GFP 
respectively. I was also responsible for DNA extraction of the Y48H plasmid, and moving 
forward these were used by a member of the Ledgerwood Lab in a NEON transfection 
protocol. Using the NEON conditions optimised by the PhD student working with the Y48H 
cytochrome c variant, an attempt was made at transfecting K562 cells with the A51V 
cytochrome c variant. The first attempt was unsuccessful (appendix F), leading to an 
optimisation protocol. Trialling several NEON conditions, there was no transfection as seen 
in figure 3.5.2B for the MLM3636_sv_neoR_CYCS_A51V_gRNA and 
pCMV_AncBE4max_P2A_GFP plasmids. Successful transfection was observed using a 
positive control, the pEFGFP reporter plasmid, indicating that the conditions trialled do work 
for K562 cells (figure 3.3A). This lead to speculation that there was an issue with the 
plasmids used as the NEON transfection system was sufficient for transfecting some 
plasmids to K562 cells.  
 
Figure 3.3. Electroporation of K562 cells using NEON transfection system. A. High efficiency 
electroporation of K562 cells with a reporter plasmid, pEFGFP. K562 transfected with 1.0 L PEFGFP 
plasmid showed successful transfection indicated by green fluorescence. Photos taken 24hr post 
transfection at 4x magnification. B. Representative image of K562 cell population transfected with 1.0 
L MLM3636 sv neoR CYCS A51V gRNA and 0.5 L pCMV AncBE4max P2A GFP 
plasmids. Images taken on brightfield and GFP. 0.2x106 cells/well were seeded in 24 WP. Photos 
taken at 4X magnification. 
A B 
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3.4 Impact of the inhibition of mitochondrial ROS production on 
PMA induced megakaryocytic differentiation 
S1QEL and S3QEL inhibit mitochondrial ROS production from two separate sites in the 
ETC. S1QEL inhibits superoxide production from site IQ (redox site complex I)49 and S3QEL 
inhibits superoxide production at site IIIQo (redox site complex III)50. Mitochondrial ROS are 
suspected to have a role in haematopoiesis37, and recently ROS production has been reported 
to enhance thrombopoiesis39, leading to speculation that mitochondrial ROS are important for 
MK differentiation. Therefore it was of interest to establish how restriction of mitochondrial 
ROS may impact on the differentiation potential of MKs. Inhibiting mitochondrial ROS 
production was hypothesised to impede K562 PMA induced megakaryocytic differentiation.  
 
Due to the variability in the differentiation status of K562 cells treated with PMA for six 
days, K562 cells were treated with PMA for three days only, representative of a partially 
differentiated MK. K562 cells were treated with PMA and either mitochondrial ROS 
inhibitor S1QEL or S3QEL to analyse the contribution of mitochondrial ROS to MK 
differentiation. The CD61 MFI, using the geometric mean, was calculated via flow cytometry 
to indicate megakaryocytic differentiation. Negative control samples included cells treated 
with S1QEL or S3QEL without PMA, or with DMSO only. Negative control samples showed 
no sign of differentiation indicated by low levels of CD61 MFI (table 3.4). The positive 












*No PMA only control was included in experiment one. Data shown is from 3.1.1, experiment 1.   
 
Table 3.4 outlines the CD61 MFI for K562 cells with various treatments. CD61 MFI was 
similar between K562 cells treated with S1QEL/S3QEL inhibitors compared to PMA alone, 
suggesting that mitochondrial ROS are not crucial for megakaryocytic differentiation.  
 
To further distinguish the impact of mitochondrial ROS inhibition on K562 megakaryocytic 
differentiation, the fold change in CD61 MFI was calculated for treatment samples compared 
to an untreated negative control (DMSO). After incubation with PMA for three days with 
PMA, with or without S1QEL or S3QEL, cells were prepared for flow cytometric analysis 
using a CD61 antibody to indicate level of MK differentiation.  
 
Figure 3.4 shows the fold change in CD61 MFI from PMA +S1QEL or +S3QEL, or +PMA 
treated populations compared to cells treated with DMSO. There was no significant 
difference in the fold change in CD61 MFI between PMA only treated samples and 
populations treated with either mitochondrial ROS inhibitor. This suggests that mitochondrial 
ROS are not important in K562 PMA induced megakaryocytic differentiation.  
 
 
Drug treatment Exp 1 Exp 2   Exp 3  
S1QEL   12.4 7.44 11.9 
S1QEL+PMA  275 198 56.6 
S3QEL  10.1 9.36 13.7 
S3QEL+PMA  191 120 268 
PMA 250* 156 182 
DMSO 10.9 3.22 13 
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Figure 3.4. Fold change in CD61 MFI from DMSO in the presence of mitochondrial ROS 
inhibitors. K562 cells were treated with PMA as per previous differentiation assays. Either 
S1QEL or S3QEL were added alongside PMA to investigate the impact mitochondrial ROS 
had on K562 megakaryocytic differentiation. Data shown as a fold change in CD61 MFI 
comapred to DMSO sample, mean ±SD, n=2 (+PMA), n=3 (PMA +S1QEL/S3QEL).  P > 0.05 





This study is among the first to investigate the metabolism of MKs throughout their 
differentiation. The study was part of an ongoing project by the Ledgerwood Lab group who 
are investigating the association between CYCS mutations and thrombocytopenia. The group 
have previously determined that enhanced apoptotic activity of variant cytochrome c is not 
likely to cause thrombocytopenia, and a focus has since been put on investigating the 
functions of variant cytochrome c in mitochondrial respiration29. Contributing to current 
research by the Ledgerwood Lab, this project aimed to describe a suitable cell model that was 
representative of MKs during their maturation from HSCs. In turn, this would allow for 
investigation of how MKs use energy, potentially identifying an avenue where variant 
cytochrome c may alter regular MK activity. The mitochondrial activity in MKs throughout 
differentiation was the primary focus of this research and was investigated by looking at the 
respiratory capacity of K562 cells treated with PMA which induces megakaryocytic 
differentiation. The contribution of mitochondrial ROS was also assessed by treating cells 
with specific inhibitors of site IQ and site IIIQo. 
 
4.1 PMA induced megakaryocytic differentiation of K562 cells  
Initial work was directed at establishing a model for MK differentiation. As noted previously, 
MKs arise from HSCs through a stepwise differentiation model, existing as progenitor cells 
in intermediate states of differentiation before reaching full maturation51. To characterise a 
cell model representing both partially and fully differentiated MKs, K562 cells were treated 
with PMA. It has been well established that PMA induces K562 megakaryocytic 
differentiation52, however there was no defined protocol to distinguish a partially 
differentiated cell model from a fully differentiated cell. A key marker of MK differentiation 
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is CD61, part of a heterodimeric glycoprotein complex expressed exclusively on the surface 
of platelets and MKs53. This study showed that treatment with PMA for six days increased 
the amount of CD61 expressed by K562 cells when compared to cells treated with PMA for 
three days (figure 3.1.2A). Treatment with PMA for nine days showed a reduction in CD61 
expression, likely by reduced cell viability (31.2.B). PMA has been reported to induce 
apoptosis in K562 cells, a possible explanation for the reduced CD61 expression seen in the 
nine day treated cells54, 55. Nine-day incubation with PMA may have resulted in increased 
apoptotic K562 cells, ultimately leading to the cell population dying. Therefore, the cells 
which survived were those that did not respond to PMA and did not differentiate, resulting in 
little CD61 expression. Furthermore, the differentiation assay conditions were suited to 
undifferentiated K562 cells and therefore by nine days the differentiated population may not 
have been able to survive.  
 
Surprisingly, when using the established MK cell model in future experiments, the level of 
CD61 expression was not reproducible in the six-day treated population. When determining 
the differentiation status of cells used in the Seahorse Cell Mito Stress tests, it was noted that 
the fully differentiated model had less CD61 MFI than the partially differentiated model 
(figure 3.2.2.2). The variability in megakaryocytic differentiation status of K562 cells raises 
the question on the validity of the initial cell model described. The expression of CD61 alone 
may not be the most accurate depiction of complete MK maturation. To better distinguish 
fully differentiated MKs from partially differentiated MKs, the level of CD41 expression 
should be assessed. Glycoprotein GpIIb (CD41) makes up the other half of the heterodimeric 
glycoprotein complex alongside GpIIIa (CD61)56. By determining the fraction of the cell 
population that is both CD41 and CD61 positive, this would better reflect a fully 
differentiated MK. This idea aligns with a previous study which showed that CD61 and 
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CD41 expression were both markers of MK differentiation57. Furthermore, a partially 
differentiated MK model may be better represented by cells which are positive for only one 
glycoprotein, CD61 or CD41.  
 
When completing the Seahorse Cell Mito Stress tests, it was observed that the harvested cell 
pellet for K562 +PMA six days was far larger than the three-day treated sample. This is likely 
indicative of continual cell growth and lack of differentiation, consistent with the lower 
CD61 MFI for six day treated cells compared to three-day treated cells as shown in figure 
3.2.2.2. PMA induces cell cycle arrest by activating PKC, driving flux through the MAPK 
pathway45. Activation of downstream signaling events ultimately lead to megakaryocytic 
differentiation, restricting cell division. In future experiments, it would be beneficial to 
measure the confluency of the cell populations to judge whether cell cycle arrest had 
occurred or whether the cells were continuing to grow. The variation in differentiation status 
of K562 cells between experiments renders the following results from this study 
inconclusive. Claims cannot be made on the energy use of differentiating MKs when the cell 
model used does not reflect a differentiating MK, however this was not established until 
metabolic experiments were well underway. Future work should look at re-defining a 
differentiating MK cell model. 
 
4.2 Cellular bioenergetics of K562 cells treated with PMA  
The association between CYCS mutations and thrombocytopenia was identified over a decade 
ago, yet there is still significant work to be done to elucidate the mechanisms behind this 
correlation. The current literature is conflicting on the functionality of variant cytochrome c, 
with some reports detailing changes in the redox capacity of the protein22, 27, and some 
reporting no differences when compared to the wild type protein1, 28. To better understand the 
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link between CYCS mutations and thrombocytopenia, it is important to first have a solid 
understanding of the energy demands of MKs.  
 
Little is understood about the energy requirements of MKs as they differentiate. Due to the 
energy expensive cytoplasmic and cytoskeletal remodeling that occurs to project proplatelets, 
it is thought that MKs have increased energy demands as they mature. The main source of 
energy for a majority of cell types is oxidative phosphorylation, whereby the ETC facilitates 
the oxidation of oxygen to make ATP33. It is theorized that MKs rely on oxidative 
phosphorylation for energy, not only to meet the suspected high energy needs of mature MKs 
but furthermore because they favour an oxygen rich environment58. Mature MKs exist in the 
bone marrow vascular niche a high oxygen environment, compared to HSCs which reside in 
the hypoxic osteoblastic niche59. For this reason, they are thought to utilise the abundance of 
oxygen and drive flux through the ETC, differing from HSCs which rely largely on 
glycolysis60.  
 
The results from this study do not support the hypothesis that mature MKs have greater 
energy demands than their precursors. Figure 3.2.2.1B indicates that there is no significant 
difference in OCR between K562 cells treated with PMA for three or six days compared to 
WT K562 cells. Although this is the first study comparing the changes in OCR when the ETC 
is manipulated in partially and fully differentiated MKs, the results suggest that MKs have 
similar energy requirements regardless of level of differentiation. A study by Huang et al. 
(2014) reported that PMA induced MK differentiation of K562 cells resulted in decreased 
maximum oxygen uptake within the first 24 h of treatment54. They furthermore showed that 
oxygen consumption was returned to control levels by 72 h. It is therefore possible that by 
measuring the OCR in untreated K562 cells and in cells treated for three or six days 
 52 
overlooked a crucial time point in the differentiation process where the metabolic demands 
varied. It would be beneficial to measure OCR at more time points, for example every 24 h 
post PMA treatment, to elucidate whether there is a variation in the metabolic needs of MKs 
during earlier stages of differentiation. Huang et al did only report the overall oxygen uptake 
by K562 cells post PMA treatment, whereas this study looked more specifically at the 
changes in OCR in response to manipulation of the mitochondrial ETC providing a more 
comprehensive and specific report on OCR. Therefore, the two studies are not totally 
comparable.  
 
Variability in CD61 MFI of K562 cells treated with PMA measured throughout this project 
meant that the results from the Seahorse Cell Mito Stress test were not applicable to partially 
or completely differentiated MKs. The correlation between OCR and CD61 MFI was 
determined to better understand any potential relationship between differentiation status and 
OCR (figure 3.2.2.3). No significant differences were identified, however the r value 
indicated that there was a positive correlation between the OCR and level of CD61 MFI in 
K562 cells (table 3.2). This suggests that cells that are more differentiated may have a greater 
capacity for mitochondrial respiration to support higher energy needs. This finding follows 
with hypotheses from the literature, whereby platelet production is an energy expensive 
process51. By increasing the respiratory capacity in mature MKs it may lead to more efficient 
platelet production. Furthermore, mature MKs are large polyploid cells, around 10-15 times 
larger than a typical red blood cell61, and it is possible that they have greater energy demands 
in order to support their large mass. The correlations from this study are non-significant and 
the possibility that they are due to chance cannot be excluded. Future work should look at 
repeating the entire Seahorse Cell Mito Stress tests using an optimised differentiation assay. 
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By developing a more accurate model of differentiating MKs, the correlation between OCR 
and CD61 MFI can be better analysed.  
 
4.3 PMA acts independently of promoting cell cycle arrest to 
increase ECAR 
The difference in basal ECAR observed in figure 3.2.2.4 is surprising as there was no 
significant difference in basal OCR between K562 cells treated with 0.5 nM PMA for three 
or six days (figure 3.2.2.1). ECAR is obtained via measuring the proton release into cell 
media from lactate production, which is indicative of the amount of glycolysis occuring. 
Lactate is produced via the breakdown of pyruvate, a product of glycolysis. It is likely that 
PMA is having an effect on K562 cells independent of inducing differentiation. Phorbol 
esters, such as PMA, are classed as tumour promoting molecules. Activation of PKC by 
phorbol esters can lead to the promotion of cellular proliferation pathways, as well as 
differentiation. PMA has a variety of roles in metabolism influenced by factors such as its 
cellular localisation and phosphorylation state62. Tumorigenesis is well described to be 
accompanied by a switch in metabolism whereby cells rely more heavily on glycolysis for 
energy63. This may, in part, explain the increased ECAR for cells treated with PMA. A study 
investigating both the MAPK independent and dependent effects of PMA induced changes in 
K562 cells reported increased tyrosine phosphorylation of CrkL45, a feature of leukemia64. 
Therefore, activation of PKC by PMA may in fact be promoting tumour-like properties of 
K562 cells, promoting flux through glycolytic pathways, increasing ECAR. Furthermore, it 
has been reported that PMA specifically increases glycolysis in chicken embryo fibroblasts65, 
in concurrence with the findings in figure 3.2.2.3. Although it may appear that K562 cells 
treated with PMA for three days have an increased dependence on glycolytic pathways, it is 
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more likely that PMA is having an effect other than differentiation because the OCR did not 
significantly differ between cell populations. It would be beneficial in future experiments to 
evaluate the level of MAPK pathway activation by PMA to deduce how it is promoting 
differentiation. Furthermore, testing for off target pathway activation would validate the exact 
impact PMA is having on K562 cells.  
 
4.4 Impact of mitochondrial ROS inhibitors on PMA induced K562 
differentiation  
Traditionally ROS were thought to be harmful by-products of metabolism, however there is 
currently a growing understanding that they play an important role in regulating cellular 
activity. ROS have been described to be important for HSC differentiation, including through 
the MK specific lineage37. By inhibiting NADPH oxidase, a plasma membrane bound protein 
responsible for the production of cytosolic ROS, MK differentiation in CD34+ derived blood 
cells was inhibited66. This early study was supported by further research that showed 
sustained ROS production by irradiation was important in increasing the fraction of CD41+ 
cells67. The results in this study support these findings as specific inhibition of mitochondrial 
ROS had no impact on the ability of K562 cells to differentiate (figure 3.4). Based on these 
findings, it is suggested that ROS production from NADPH oxidase has greater importance in 
MK differentiation than mitochondrial ROS. This is somewhat surprising as mitochondria are 
known to be the cells’ main source of intracellular ROS37. Due to the variability in the 
differentiation status of K562 cells treated with PMA for six days, the impact of 
mitochondrial ROS on differentiation was evaluated using a three-day differentiation model. 
As it has been shown that K562 cells are able to be more completely differentiated (figure 
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3.1), the assay should be completed using a completely differentiated MK model; 
mitochondrial ROS may be important in later stages of differentiation. 
 
Conversely to the results in this study, a recent report details that inhibition of ROS from 
NADPH oxidase has no impact on the ability of CD34+ derived MKs to form proplatelets39. 
The study furthermore showed that reduction of mitochondrial ROS by mitochondrial 
superoxide scavenger MitoTEMPO, was sufficient to reduce proplatelet formation39. 
Furthermore, they showed that suppression of SIRT-3 which ultimately increases 
mitochondrial superoxide levels by preventing its conversion to hydrogen peroxide increased 
the proportion of proplatelet forming MKs. This study was completed using MKs derived 
from CD34+ blood cells, therefore the findings are more applicable in vivo. In support of this 
latter study, an investigation of MK maturation reported an increase in ROS in DAMI cells 
treated with PMA to induce MK differentiation68. This was coupled with a reduced 
mitochondrial membrane potential, suggesting that the mitochondrial membrane was 
permeabilised, leading to the conclusion that PMA induces mitochondrial ROS production 
which is important for MK maturation. The increase in ROS by PMA may explain the lack of 
effect that S1QEL and S3QEL had on K562 differentiation. It is possible PMA was acting 
elsewhere to PKC activation, leading to an increase in ROS production from other redox sites 
within the cell, compensating for the reduction in ROS produced from site IQ and site IIIQo. 
The study did not offer a  clear mechanism for how PMA increases ROS production, 
therefore it cannot be ruled out that the findings in this study are real, and mitochondrial ROS 
do not have as great of an impact on MK differentiation.  
 
Mitochondrial ROS are produced from seven independent sites on the mitochondrial 
membrane36. Site IQ and site IIIQo are characterised to produce the highest volumes of 
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superoxide (nearly 2.5 mol/min/mg protein each), however oxoglutarate dehydrogenase 
produces superoxide at a rate of nearly 1.5 mol/min/mg protein36. Oxoglutarate 
dehydrogenase, along with the other sites of mitochondrial superoxide production may be 
sufficient to sustain the ROS levels required for MK differentiation. Furthermore, this study 
only investigated inhibition of ROS from either site IQ or site IIIQo, not both; it could be that 
ROS levels were not decreased enough to see a true effect on differentiation. It would be 
beneficial in future experiments to examine the impact of inhibiting both site IQ and site IIIQo 
simultaneously. To better understand the importance of mitochondrial ROS in MK 
differentiation, a dose response assay should be completed and ROS levels measured. This 
would quantify how much mitochondrial ROS contribute to MK differentiation, and identify 
the optimal drug concentration required to inhibit ROS production. In future experiments, a 
positive control should be included to show how much ROS production decreases with 
treatment of S1QEL and S3QEL.  
 
4.5 Developing K562 cell model with cytochrome c variant 
To better understand the association of cytochrome c variants and thrombocytopenia, a cell 
model expressing CYCS mutations was aimed to be developed. The results from the NEON 
transfection in figure 3.3 indicate that this was unsuccessful. pCMV_AncBE4max_P2A_GFP 
(base editing plasmid) has a green fluorescent protein (GFP) attached that reports successful 
plasmid uptake via microscopy. The lack of fluorescence in figure 3.3 showed that K562 
cells treated under the NEON conditions trialled did not take up the 
MLM3636_sv_neoR_CYCS_A51V_gRNA (A51V guide RNA) or the base editing plasmid, 
as successful electroporation of one plasmid is assumed to indicate the success of the other. 
However, concurrent experiments using the Y48H plasmid by another member of the 
Ledgerwood Lab showed successful transfection. This, along with successful transfection of 
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the pEFGFP reporter plasmid (figure 3.3A) indicates that K562 cells are able to be 
transfected. The first NEON transfection failed; however, the cells were of a high passage 
number (13), and therefore subsequent transfections were completed using fresh cells. The 
DNA plasmids themselves may have been of poor quality, explaining the failed transfection. 
The 260/280 ratio is an indicator of the DNA purity, with a range between 1.80-2.0 indicating 
a pure sample. The 260/280 ratio for the base editing plasmid was 1.74, and for the A51V 
plasmid was 1.77, indicating an okay purity level overall. The suboptimal 260/280 ratios are 
potentially explained by endotoxin contamination. During the DNA extraction process using 
the ZymoPURE midiprep kit, the EndoZero step was completed which aims to lower the 
chance of endotoxin contamination by around 75% but does not totally exclude the 
possibility of endotoxin contamination. Future NEON transfections should be completed 
using fresh plasmids and K562 cells. 
 
Limitations 
A major limitation to this study was the lack of MK differentiation markers tested. The 
differentiation status of K562 cells was determined based solely on CD61 expression. As 
discussed previously, CD41 is another viable MK differentiation marker. Furthermore, 
analysis of the MAPKK pathway activation would be beneficial to confirm that the activity 
of PMA was specific to promoting differentiation. To better classify a partially differentiated 
MK model, microscopic techniques should be used to evaluate the morphology of the cells. 
MKs are well characterised to undergo extensive morphological changes that can be detected 
by microscopy, allowing for a better definition of differentiating MK model.  
 
During the mitochondrial ROS experiments, there was no positive control. Inhibition of ROS 
production was assumed based on previous literature. It is therefore impossible to determine 
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whether the drug concentrations used were sufficient to inhibit ROS production, and if these 
results are in fact due to a reduction in mitochondrial ROS. Mitochondrial ROS levels can be 
analysed using molecular probes such as MitoSOX which are then measured using 
fluorescence technologies39.  
 
A limitation to this study was that it entirely relied on the use of cell lines. K562 is a human 
leukemic cell line, therefore possesses tumorigenic properties. Although K562 are well 
characterised to undergo MK differentiation, WT K562 cells do not reflect undifferentiated 
MKs. The use of K562 cells do not accurately reflect in vivo MKs, and it would be beneficial 
to consider using more accurate models. These may include induce pluripotent stem cells 
(IPSCs) or primary cells. The use of IPSCs involves programming cells to undergo MK 
differentiation using transcription factors GATA1, FLI1, and TAL169, 70. MKs developed 
form human pluripotent stem cells may produce more consistent differentiation data, and 
their results will be more applicable. Primary cells offer similar advantages. It is possible to 
obtain CD34+ blood cells promote MK differentiation with various cytokines71. By 
developing a differentiating MK cell model using cells more similar to in vivo MKs, this 
would likely control for the variability seen in this report.  
 
Future directions 
The following studies would help to optimise the experiments undertaken in this report to 
produce more conclusive findings, as well as further investigating the energy needs of MKs. 
Furthermore, they may contribute to elucidating the relationship between variant cytochrome 
c and thrombocytopenia: 
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• Due to the variability in differentiation status of the K562 cells used in this report, 
optimising a differentiating MK cell model is essential for future investigations on 
MK metabolism. This would require assessing multiple differentiation markers as 
discussed previously, as well as investigating the use of other cell lines such as 
MEG01.  
• To strengthen the relevance of these findings in vivo, it would be beneficial to develop 
a differentiating MK cell model using primary cells (CD34+ derived MKs) or IPSCs 
as the biology of these cells are more similar to in vivo MKs.  
• Completing a dose response assay to optimise the mitochondrial inhibitor assay 
alongside the inclusion of a positive control would be ideal to show that the inhibitors 
are in fact inhibiting mitochondrial ROS production. Furthermore, this would allow 
for assessment of the minimum mitochondrial ROS required to have an effect on MK 
differentiation.  
• Looking at the impact of S1QEL and S3QEL on MK differentiation over a longer 
time course and at multiple time points would allow for the determination when 
mitochrondrial ROS are needed in MK differentiation.  
• Western blotting for activated pathway components in cells treated with PMA would 
allow for elucidation of the exact intracellular impact PMA is having. This would also 




The results from this study indicate that further work is required to establish a suitable cell 
model to represent differentiating MKs. It is possible that K562 cells are not the best cell line 
to represent partially differentiated MKs, and it may be more suitable to use primary cells 
such as CD34+ derived blood cells or IPSCs. The differentiation data highlights the need for 
multiple MK differentiation markers to be assessed in order to determine the true 
differentiation status of K562 cells.  
 
The changes in OCR in K562 cells indicate that the Seahorse Cell Mito Stress test is a 
suitable method for evaluating the mitochondrial respiratory capacity of K562 cells. 
Although no significant difference was reported between cells treated with PMA for three or 
six days, the optimisation of the Seahorse protocol was successful to show that K562 cells 
will respond in the assay. For the benefit of future experiments, this protocol can be applied 
in investigations of the mitochondrial respiratory capacity of differentiating MKs, using an 
optimised cell model. Furthermore, this protocol can be applied to K562 cells expressing 
variant cytochrome c proteins to evaluate its impact on mitochondrial respiration. This could, 
in hopes, reveal a mechanism by which CYCS mutations lead to thrombocytopenia.  
 
The contribution of mitochondrial ROS to the differentiation capacity of K562 cells remains 
unclear based on these results. It has highlighted the need for future investigations, including 
a dose response assay to distinguish an optimal concentration of S1QEL and S3QEL to 
reduce ROS levels.  
 
 61 
Overall, the results from this study do not support the initial hypotheses described. They do 
however open multiple avenues for future investigations into the energy demands of 
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Appendix A. CD61 MFI for PE isotype and unstained (UN) samples from differentiation 
experiments 
Day 0 3 5 6 9 
UN  2.31 missing 5.87 7.84 7.99 
PE Isotype 2.42 6.29 6.24 13.6 10.8 















Appendix B. Representative images from poly-L-lysine adhesion tests using wild type K562 
cells (A, B, C) and K562 cells treated with PMA for three days (D, E, F). 0.6x106 cells/ml 
seeded in 24WP. A/D. Prewash test. B/E. Post 1x wash. C/F. Post 3x washes. All images taken 











Appendix C. Representative images of Cell-Tak coated plate post Seahorse XF flux analysis. 

















Appendix D. CD61 MFI for PE isotype and unstained samples   
exp 1 exp 1 exp 3 exp 3 exp 4 exp 4 exp 5 exp 5 
Day 3 6 3 6 3 6 3 6 
UN  6.42 5.42 4.13 4.07 3.81 3.19 3.99 3.02 
PE isotype 5.11 missing 4.29 4.27 3.85 3.28 3.87 2.88 














































Appendix E. CD61 MFI for PE isotype and unstained (UN) 
Sample UN PE isotype 
Day 6 no media change 2.59 2.47 
Day 6 media change 
-PMA 
2.66 2.63 
Day 6 media change 
+PMA 
2.54 2.69 
9 day (1) 1.28 1.43 
9 day (2) 1.84 1.9 
9 day (3) 1.52 1.69 
9 day (4) 1.41 1.55 
Flow cytometry analysis of CD61 MFI for cells used in long term differentiation optimisation 









Appendix F. Seahorse OCR trace from optimisation experiment two. The decrease in OCR at approx. 
20 min indicates K562 cells responding to 10 M oligomycin. Subsequent increase OCR depict 
response to FCCP and maximal respiratory capacity. Decrease in OCR at approx. 60 min indicates a 
response to rotenone/antimycin A. Each line is representative of the changes in OCR in one well. 



















Appendix G. Representative image of initial NEON transfection with WT K562 cells. 0.2x105 
cells/well were seeded in 24WP. MLM3636_sv_neoR_CYCS_A51V_gRNA and 
pCMV_AncBE4max_P2A_GFP plasmids were unsuccessfully transfected into K562 cells, 
shown by lack of green fluorescent protein expression. All wells imaged showed the same 
result, magnification 4X.  
 
 
 
 
 
 
 
 
 
 
 
